The largest international study of multiple myeloma, in which more than 1,700 patients participated, netted Amgen a new approval from the U.S. Food and Drug Administration. The Thousand Oaks biotech company announced Jan. 5 that its treatment Xgeva had gotten approval from regulators to treat multiple myeloma patients after showing that it effectively blocks proteins…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
